Sangamo BioSciences | SGMO - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Alaunos Therapeutics USD 1.29M 865K 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Alterity Therapeutics Limited AUD 36.21M 18.58M 2025-12
Amgen USD 9.19B 532M 2026-03
Bayer EUR 28.85B 2.9B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Cipla INR 344.32B 15.13B 2026-03
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 102.73M 58.9M 2025-12
CSL USD 18.66B 2.75B 2025-12
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Grifols EUR 6.21B 133.12M 2025-12
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Merck USD 45.88B 6.73B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Omeros USD -228.68M 15.13M 2025-06
Pfizer USD 90.1B 3.63B 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03